Cargando…
Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments
INTRODUCTION: Patients with cancer (PC) are at high risk of acquiring COVID-19 and can develop more serious complications. Deeper understanding of vaccines immunogenicity in this population is crucial for adequately planning vaccines programs. The ONCOVac study aimed to comprehensively assess the im...
Autores principales: | Cortés, Alfonso, Casado, José L., Longo, Federico, Serrano, Juan J., Saavedra, Cristina, Velasco, Héctor, Martin, Adrián, Chamorro, Jesús, Rosero, Diana, Fernández, María, Gion, María, Martínez Jáñez, Noelia, Soria Rivas, Ainara, Alonso Gordoa, Teresa, Martínez Delfrade, Íñigo, Lage, Yolanda, López Miranda, Elena, Olmedo, María E., Reguera Puertas, Pablo, Gajate, Pablo, Molina Cerrillo, Javier, Guerra Alia, Eva, Fuentes Mateos, Raquel, Romero, Beatriz, Rodríguez-Domínguez, Mario J., Vallejo, Alejandro, Carrato, Alfredo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885286/ https://www.ncbi.nlm.nih.gov/pubmed/35316750 http://dx.doi.org/10.1016/j.ejca.2022.02.017 |
Ejemplares similares
-
Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022) -
Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors
por: Saavedra, Cristina, et al.
Publicado: (2023) -
112P Immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in cancer patients receiving immunotherapy agents
por: Muñoz, F. Longo, et al.
Publicado: (2021) -
Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma
por: San-Román-Gil, María, et al.
Publicado: (2023) -
Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature
por: Albarrán, Víctor, et al.
Publicado: (2023)